Pharma major Dr Reddy's Laboratories Ltd on Tuesday reported 76 per cent decline in consolidated net profit for the first quarter of 2016-17, at Rs 154 crore as against Rs 647 crore in like period year ago.
In a regulatory filing to the stock exchange BSE, the city-based group company said consolidated income for the quarter under review also declined 14 per cent to Rs 3,290 crore from Rs 3,828 crore in same period year ago.
On standalone basis, the parent company's net profit declined 17 per cent to Rs 409 crore in Q1 from Rs 493 crore year ago, while income dipped 3.9 per cent to Rs 2,533 crore from Rs.2,634 crore year ago.
"We have come through a very difficult first quarter, with our top and bottom lines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela," said Dr Reddy's Chief Executive G.V. Prasad in a statement.
--IANS
fb/vd
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
